MétaCan
← all works

Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci

2007· article· en· 417 citations· W2129356845 on OpenAlex· 10.1158/0008-5472.can-06-3948

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.

The three-model screen

all 1,000 screened works →

All three models called this out of scope.

stratum: aff_core · design weight: 5595.24 (the sample is stratified; any rate computed without the weight is wrong)
Claude Opus 4.8OUT
genre: empirical
about Canada: no
confidence: high

Development of a chlorotoxin bioconjugate for intraoperative cancer visualization; the object is an imaging agent.

GPT-5.6 (high)OUT
genre: empirical
about Canada: no
confidence: high

It develops an optical cancer-imaging agent, not a study of research.

Grok 4.5OUT
genre: empirical
about Canada: no
confidence: high

Cancer imaging bioconjugate (tumor paint); translational oncology tool, not research-on-research.

Abstract

Toward the goal of developing an optical imaging contrast agent that will enable surgeons to intraoperatively distinguish cancer foci from adjacent normal tissue, we developed a chlorotoxin:Cy5.5 (CTX:Cy5.5) bioconjugate that emits near-IR fluorescent signal. The probe delineates malignant glioma, medulloblastoma, prostate cancer, intestinal cancer, and sarcoma from adjacent non-neoplastic tissue in mouse models. Metastatic cancer foci as small as a few hundred cells were detected in lymph channels. Specific binding to cancer cells is facilitated by matrix metalloproteinase-2 (MMP-2) as evidenced by reduction of CTX:Cy5.5 binding in vitro and in vivo by a pharmacologic blocker of MMP-2 and induction of CTX:Cy5.5 binding in MCF-7 cells following transfection with a plasmid encoding MMP-2. Mouse studies revealed that CTX:Cy5.5 has favorable biodistribution and toxicity profiles. These studies show that CTX:Cy5.5 has the potential to fundamentally improve intraoperative detection and resection of malignancies.

Stored with the screening record, where it is evidence for the labels above.

The record

Venue
Cancer Research
Topic
Nanoplatforms for cancer theranostics
Field
Engineering
Canadian institutions
Immunovaccine (Canada)
Funders
National Cancer InstituteU.S. Public Health Service
Keywords
CancerBiodistributionCancer researchIn vivoCancer cellBioconjugationChemistryPathologyRous sarcoma virusIn vitroMedicineBiologyInternal medicineBiochemistry
Has abstract in OpenAlex
yes